In 38 patients diagnosed as adult sporadic amyotrophic lateral sclerosis (ALS), and negative for relevant anti -ganglioside, anti-borrelia or anti-Boma disease virus antibodies, we determined serum concentrations of neopterin, ~r microglobulin, immunoglobulin-G isotypes G1-G", carbohydrate antigen CA-19-9, as well as repeated enzyme linked immuno-assay (ELISA) serum antibodies to human spuma retrovirus (HSRV, human foamy virus=HFV) envelope plus gag./capsid antigen, and competition with maedi-visna virus antibodies in an blocking ELISA Confirmed by specific HFV-gag immunoblots and measured under code, 26% of tested ALS-patients and 4% of 195 other neurological controls reacted ELISA and immunoblot antibody-positive against HFV. In a maedi-visna virus blocking ELISA, 47/ 50 sera from 28/30 ALS patients competed with anti-visna lentivirus antibodies more than healthy controls (p<0.05). In serum, however, f3r microglobulin and neopterin concentrations were normal in different stages of motor neuron disease. Maximal individual mean values for serum CA-19-9, anti-visna competition or circulating IgG immune complexes associated with positive serum antibodies against human recombinant foamy retroviral antigen, while macrophage activation measured as serum neopterin did not
Introduction
Human foamy retrovirus has become a prime candidate pathogen for neurodegenerative central nervous motor disorders (I), since transgenic expression is brain-and muscle-specific (2, 3), and mice predominantly develop myatrophy and encephalopathy (4) . Recently (5, 6), we reported on an upregulated humoral immune response against human spuma retrovirus, a represent<\tive of the still incompletely §Author to whom correspondence should be addressed.
Pteridines / VoL 4 / No.2 characterized foamy retroviruses (7) , in patients with idiopathic ALS. With documented elevated circulating immune complexes (8) , cerebral lesions in magnetic resonance imaging (9) , an inverse correlation between age and duration as in HIV infection (10) , an elevated lymphoma incidence (11) and a monophasic progressive clinical course, ALS shares partial analogies with other retroviral diseases (12, 13) . In adult sporadic motomeuron disease, increased incidences have been reported for anti-retroviral and anti-ganglioside GM I antibodies; activated macro-phages have been found infiltrating the spinal cord in ALS (14) . While in ALS T-Iymphocyte subpopulations were normal (11 , 13, 14) , ~rmicroglobulin and neopterin as markers of a cellular immune response have not been documented; in autoimmune disorders neopterin levels correlate with extent and activity of the disease (15) . Neopterin and ~2-micro globulin are regularly increased in human immunodeficiency virus type-l (HlV -1) infection, elevated in a proportion of human T-Iymphotropic retrovirus (HTLV-l)-positive neurological patients (16) , yet unchanged in Parkinson's disease (17) . D-erythro-neopterin is produced by stimulated macrophages, and correlates well with in-vitro replicative capacity of HlV-l isolates (18) ; ~rmicrogJobu1in constitutes the light chain of major histocompatibility complex (MHC) class I antigens HLA-A, -B and -C, identical with thymotaxin, and present in high densities on lymphocytes. In this paper, we examine anti-retroviral antibodies, neopterin, ~2-microglobulin, carbohydrate antigen CA-19-9 and serum immunoglobulin isotypes in ALS. Anti-HFV seronegativity correlates with low IgG 3 plasma concentrations, while anti-HFV seropositivity associates with increased binding of ALS sera to maedi-visna antigen or elevated levels of circulating asialo-gangJioside CA-19-9, respectively.
Patients and Methods
Human foamy virus (HFV)=spuma retroviral (HSRV) antibodies were determined in 38 ALS patients, 396 non-ALS patients and a total of 600 coded sera as described in (1, 19) using identical recombinant HFV envPX envelope and gagCA capsid antigens (20) ; 195 Ulm neurological in-patients without acute cranial nerve affection, myelopathy or Parkinson's syndromes served as controls ("other neurological diseases"). Diagnostic criteria for 38 patients with definite idiopathic ALS (aged 19-78 years, mean age of 58.4 years) were signs of lower motor neuron involvement (fasciculations, progressive muscular wasting and weakness in the absence of progressive sensory deficits and multi focal conduction block), involvement of upper motor neuron at some stage of the disease, and possible development of bulbar symptoms and signs. No patient was suffering from recurrent or concomitant infectious diseases. including hepatitis, borreliosis or acute herpes infection, all 24 consenting patients examined were negative for antibodies to human immune deficiency virus. All patients had areactive treponema pallidum hemagglutination tests, were negative for monoclonal gammopathy, relevant anti-glycolipid antibodies to GM-l, GD-lb, GA-l , 3'-LMI and sulfatide, separately tested anti-GMI IgM antibody titers, or IgG ELISA antibodies to Boma disease virus (21) . A maedi-visna lentivirus competition ELISA was done in 50 sera available unfrozen from 30 ALS patients aged 19-78 years and tested for HFV' antibodies within three weeks. Blocking of specific polyclonal anti-visna antibodies was expressed as reduction in binding after pre-incubating visna antigen with patient sera, and standardizing blocking ELISA endpoint optical densities as described (22, 23) to values established for healthy Danish adults. Results in % reduction were compared with 28 age and sex matched patient controls (not tested for HFV) as well as 15 "other neurologic diseases" tested HFV-seronegative. Circulating IgG immune complexes (CIC) were quantitated by standard Raji cell assay (healthy references<2.4 mg/L, patient normal reference limit 14 mg/L); sera had been frozen immediately.
Results

Foamy retrovirus
Antibody seropositivity for human foamy retroviral (HFV, human spuma retrovirus) antibodies was a significant finding in idiopathic ALS (p<0.01). Examined consecutively and under code, 18/38 ALS patients reacted HFV-env and/or HFV-gag ELISA antibody positive compared with 33/195 neurological controls and 7/52 orthopedic patients (Fig. 1) . In contrast to only 8/ 195 (4%) of "other neurological controls", 26% of ALS patients could be confirmed seropositive for anti-HFV-gag antibodies by immunoblot. Over the last 24 months, 18/38 ALS patients (45%) and 34/ 195 other neurological controls (18%) had reacted either ELISA or immunoblot HFV antibody positive. Seropositivity was independent of duration of disease, age, circulating immune complexes, total cerebro-spinal fluid protein, course or variant of motor neuron disease. Of 35 patients who recalled the onset of first signs or symptoms by month, 9 HFV-positive and 9 HFV-negative patients reported a clinical onset in their upper extremities, 7 HFVpositive and 5 HFV-negative patients in their legs or feet, and 1 HFV-positive and 4 HFV-negative patients a (pseudo-) bulbar onset of the disease. Mean age at first clinical symptoms was 59.7 years for primary bulbar disease, 56.7 years for start in the upper extremities, and 53.6 years for begin in the legs (see Table 1 ). Two seropositive idiopathic ALS patients had been treated for sporadic -essential tremor" with oral propranolol for over 12 months prior to progressing to ALS. On cerebral nuclear magnetic resonance studies 5/7 anti-HFV-positive and 1/4 anti-HFV-negative motor neuron disease patients had native magnetic resonance scans unremarkable for age. Small demyelinated asymmetrical lesions in the st:bcortical layers were seen in three men (HFVnegative 51 y; HFV-positive 55 y, 62 y), whereas leftsided fronto-subcortical, corticospinal tract and rostro-external capsule lesions were seen in one woman with paretic right arm, and multiple bilateral periventricular and left-sided basal ganglia lesions in a woman with tetraparetic begin of the disease (both women aged 58 years, HFV-seronegative).
Visna lentivirns
On ELISA binding, 28 ALS sera from 23 patients competed with anti maedi-visna virus antibodies better than 28 age and sex matched geographic control patients; after pre-incubating ELISA visna antigen with neurologic sera, binding of polyclonal anti-visna antibodies expressed as relative optical density calculated against healthy Danish controls (=: 100 Fig. 2 ), and all patients measured more than once remained concordant regarding competition (28/30) or noncompetition (2/30). Visna reactivity tended to be more pronounced in sera with high maximal circulating immune complexes (see Table 1 ). In 10 patients with elevated maximal immunoglobulin-G immune complexes, mean reduction of visna antibody binding was -13.0%± 1.5 SE, compared with 16 patients with immune complexes<14 mg/L and a mean reduction in visna antibody binding of -8.8 %± 1.5 SE.
Neopterin and Brmicroglobulin
Neopterin and Brmicroglobulin concentrations were determined simultaneously in 55 sera and in nine CSF samples of 28 ALS patients, with total CSF protein concentrations ranging from 248 to 803 mg/L Monocytopenia or neutropenia as an indirect cause for altered neopterin measurements could be excluded in our patients. Three ALS patients aged 62 to 75 years exceeded the all-age neopterin referen- ce (S8.7 nmollL), measuring 9.2, 9.3, and 9.5 nmollL for neopterin, and 2.6, 2.2 and 0.6 mg/L for I3rmicroglobulin. Vsing age-adjusted reference limits for I3rmicroglobulin (S2.5 mgIL at age <60 years, and <3.2 mgIL at age >60 years), all ALS patients tested within normal ranges (Fig. 3 ). ALS patients with simultaneously high anti-HFV-env and -gag antibody titers did not differ in neopterin levels (Fig. 3b) . CSF concentrations of both I3rmicroglobu-lin and neopterin never exceeded corresponding serum levels. Including seven moribund and severely affected patients, we could not demonstrate a definite elevation of I3rmicroglobulin and neopterin in ALS; both serum concentrations correlated well (r= 0.7, p<O.01). In contrast, two repeatedly HFV ELISA-positive neurological control patients demonstrated highly elevated values of neopterin (19.4 and 50.5 nmol/L) and I3rmicroglobulin (7.0 and 9.2 mg/L); one of them (a 69-year-old man) was suffering from thyroiditis, an atypical Parkinson's syndrome and incapacitating tongue tremor, the other (a 61-year-old woman) from repeated cerebral microinfarctions with positive anti-nuclear serum antibodies (titer 1:160 and 1 :320). 
Immunoglobulin isotypes
Carbohydrate antigen CA-19-9
We compared CA-19-9 concentrations in 60 ALS sera from 15 HFV-seropositive and 20 HFV-seronegative patients, and in 10 other neurological sera from 7 HFV-seropositive patients. HFV-seronegative motorneuron patients showed a CA-19-9 distribution similar to 1539 healthy controls, and HFV-seropositive motorneuron sera (n=26) rather approximated the results from 308 patients with non-malignant gastro-intestinal disorders (Fig. 4, 26) . In both HFVseropositive ALS and HFV -seropositive other neurological patients, CA-19-9 concentrations tended towards higher carbohydrate levels. Three ALS patients exceeded the upper reference limit of 37 V l ml, two neurological control patients with Parkinsonian syndromes reproducibly demonstrated CA-19-9 levels between 23 and 34 V l ml. Individual mean concentrations of six ALS patients exceeded the reference range for healthy individuals (14 V l ml), only one of whom had never demonstrated anti-HFV antibodies in serum. In three of the HFV -seropositive ALS patients with elevated CA-19-9, no significant gastrointestinal pathology could be documented including abdominal computerized tomography. All eight patients demonstrating either more than 17.5% visna competition by 17.5% or CA-19-9 levels above 17.5 V l rnl had tested HFV antibody positive (Fig. 5) . Among ten patients without detectable CA-19-9, six had reacted HFV antibody negative (p<O.Ol, Fisher's exact test, Tables 2 and 3 ).
Discussion
More than one third of ALS sera and patients Twelve sera from ALS patients positive for anti-tested had antibodies to human spuma retrovirus (14) . basically normal ~Tmicroglobulin and neopterin levels in amyotrophic lateral sclerosis argue against a persisting, generalized macrophage response in the disease. The monoclonal antibody detecting carbohydrate antigep. CA-19-9 recognizes a ganglioside containing glycosylated lacto-N-fucopentose-II (28). Both in HFV-seropositive ALS and HFV-antibody positive other neurological patients all negative for anti-GM\ ganglioside antibodies, CA-l9-9 concentrations seemed to be distributed similar to patients with non-malignant gastro-intestinal disorders (26) . Maximal anti-HFV seroreactivity cosegregates with both anti-visna competition and elevated CA-19-9 serum ganglioside (Fig. 4) . A cross-reactivity of unidentified macromolecules may contribute to anti-ganglioside reactivities in neurologic patients (29) .
Anti HSRV-seronegativity (not anti-visna blocking activity) segreated with low IgG 3 serum concentrations. IgG 3 represents a predominant isotype in clearing intracerebral alphavirus encephalitic infection (32) , and low IgG 3 concentrations are found in disimmune disorders and chronic fatigue syndrome (33). If HFV-seroreactivity does not characterize a disease variant, low circulating IgG 3 in HFV-seronegative ALS could result from specific or non-specific antibody sequestration. In ALS, clinical progression patterns (34), a "remarkably regional disease" (35), elevated circulating immune complexes (36, 8, 10, 37), . non-inflammatory dermal alterations (10, 37, 38, 39) , an inverse correlation between age and duration (10), and elevated lymphoma incidence (40, 11) partially remind of other retroviral diseases (41, 13) . Nevertheless, we have neither observed any epidemiologic peculiarity of anti-retroviral seroreactive ALS patients, nor detected foamy viral genomic information in lymphocytes of HFV antibody-positive indi-87 viduals up to now; there is, however, foamy-retrovirus immunoreactive antigenemia in ALS patients (unpublished). A regional, low-active retroviral expression. potentially expanding without completion of viral particles (42), would be compatible with both antiretroviral seroreactivities and a lack of evidence for generalized lymphoproliferation. In known retroviral central nervous system diseases with immune stimulation, increased concentrations are reported for interleukin-6 (43), soluble tumor necrosis factor receptor (44) or quinolinic acid (45) . Though their production depends on macrophage stimulation and endogenous interferon-gamma production not observed in ALS, studies clarifYing this issue are needed. In motor neuron disease in general, and ALS in particular, the immune system seems to be altered in rather peculiar ways (30), and younger patients or patients with multi focal conduction block, antiganglioside antibodies and immunoglobulin abnormalities may live longer than respective control patients (31) . Whether retroviral serology, carbohydrate antigen, or immunoglobulin-G isotyping help identify diagnostic or prognostic subgroups remains to be elucidated.
Accompanied by diverse changes in the humoral immune response (46) , the observed anti-retroviral seroreactivity could be due to a) an exogenous agent partially homologous to HFV and maedi-visna virus altering the host immune system (47), b) human endogenous retrovirus-like sequences (HERY) that may comprise 0.1-0.6% of the human genome (48) and mimick an anti-human foamy retroviral immune response, or c) a complex interaction of exogenous and/or endogenous retroviral sequences (49) with host genes or gene products. HFV indeed transactivates other retroviral agents (50) . In experimental retroviral motor neuron disease, mice suffer a nonimmunogenic retroviral injury to anterior hom neurons (12) , and in natural rodent motor neuron disease, the translation products of endogenous murine leukemia retrovirus serve as surrogate receptor for another viral agent, lactate dehydrogenase-elevating virus (51) . If transgenic mice defective for ciliary neuronotrophic factor (52) similar to mice expressing human foamy virus genes (4) die with progressive muscular atrophy, -though CNTF mRNA is preserved in ALS spinal cord-, a retroviral interference with cellular signaling may be responsible (53) .
